Literature DB >> 22969153

Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions.

Rogier A van Dijk1, Frank Kolodgie, Amir Ravandi, Gregor Leibundgut, Patrick P Hu, Anand Prasad, Ehtisham Mahmud, Edward Dennis, Linda K Curtiss, Joseph L Witztum, Bruce A Wasserman, Fumiyuki Otsuka, Renu Virmani, Sotirios Tsimikas.   

Abstract

The relationships between oxidation-specific epitopes (OSE) and lipoprotein (a) [Lp(a)] and progressive atherosclerosis and plaque rupture have not been determined. Coronary artery sections from sudden death victims and carotid endarterectomy specimens were immunostained for apoB-100, oxidized phospholipids (OxPL), apo(a), malondialdehyde-lysine (MDA), and MDA-related epitopes detected by antibody IK17 and macrophage markers. The presence of OxPL captured in carotid and saphenous vein graft distal protection devices was determined with LC-MS/MS. In coronary arteries, OSE and apo(a) were absent in normal coronary arteries and minimally present in early lesions. As lesions progressed, apoB and MDA epitopes did not increase, whereas macrophage, apo(a), OxPL, and IK17 epitopes increased proportionally, but they differed according to plaque type and plaque components. Apo(a) epitopes were present throughout early and late lesions, especially in macrophages and the necrotic core. IK17 and OxPL epitopes were strongest in late lesions in macrophage-rich areas, lipid pools, and the necrotic core, and they were most specifically associated with unstable and ruptured plaques. Specific OxPL were present in distal protection devices. Human atherosclerotic lesions manifest a differential expression of OSEs and apo(a) as they progress, rupture, and become clinically symptomatic. These findings provide a rationale for targeting OSE for biotheranostic applications in humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22969153      PMCID: PMC3494262          DOI: 10.1194/jlr.P030890

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  44 in total

Review 1.  Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications.

Authors:  Ira Tabas; Kevin Jon Williams; Jan Borén
Journal:  Circulation       Date:  2007-10-16       Impact factor: 29.690

2.  Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway.

Authors:  Baohai Shao; Subramaniam Pennathur; Ioanna Pagani; Michael N Oda; Joseph L Witztum; John F Oram; Jay W Heinecke
Journal:  J Biol Chem       Date:  2010-04-08       Impact factor: 5.157

3.  Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

Authors:  Frederick J Raal; Raul D Santos; Dirk J Blom; A David Marais; Min-Ji Charng; William C Cromwell; Robin H Lachmann; Daniel Gaudet; Ju L Tan; Scott Chasan-Taber; Diane L Tribble; Joann D Flaim; Stanley T Crooke
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

4.  Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.

Authors:  Esther Merki; Mark J Graham; Adam E Mullick; Elizabeth R Miller; Rosanne M Crooke; Robert E Pitas; Joseph L Witztum; Sotirios Tsimikas
Journal:  Circulation       Date:  2008-07-28       Impact factor: 29.690

5.  Intraplaque hemorrhage and progression of coronary atheroma.

Authors:  Frank D Kolodgie; Herman K Gold; Allen P Burke; David R Fowler; Howard S Kruth; Deena K Weber; Andrew Farb; L J Guerrero; Motoya Hayase; Robert Kutys; Jagat Narula; Aloke V Finn; Renu Virmani
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

6.  The role of oxidized phospholipids in atherosclerosis.

Authors:  Judith A Berliner; Norbert Leitinger; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2008-12-04       Impact factor: 5.922

7.  A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma.

Authors:  Claes Bergmark; Asheesh Dewan; Alexina Orsoni; Esther Merki; Elizabeth R Miller; Min-Jeong Shin; Christoph J Binder; Sohvi Hörkkö; Ronald M Krauss; M John Chapman; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2008-07-01       Impact factor: 5.922

8.  Relationship of thrombus healing to underlying plaque morphology in sudden coronary death.

Authors:  Miranda C A Kramer; Saskia Z H Rittersma; Robbert J de Winter; Elena R Ladich; David R Fowler; You-Hui Liang; Robert Kutys; Naima Carter-Monroe; Frank D Kolodgie; Allard C van der Wal; Renu Virmani
Journal:  J Am Coll Cardiol       Date:  2009-10-08       Impact factor: 24.094

9.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.

Authors:  Pia R Kamstrup; Anne Tybjaerg-Hansen; Rolf Steffensen; Børge G Nordestgaard
Journal:  JAMA       Date:  2009-06-10       Impact factor: 56.272

10.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

Authors:  Robert Clarke; John F Peden; Jemma C Hopewell; Theodosios Kyriakou; Anuj Goel; Simon C Heath; Sarah Parish; Simona Barlera; Maria Grazia Franzosi; Stephan Rust; Derrick Bennett; Angela Silveira; Anders Malarstig; Fiona R Green; Mark Lathrop; Bruna Gigante; Karin Leander; Ulf de Faire; Udo Seedorf; Anders Hamsten; Rory Collins; Hugh Watkins; Martin Farrall
Journal:  N Engl J Med       Date:  2009-12-24       Impact factor: 91.245

View more
  54 in total

Review 1.  Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

Review 2.  Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics.

Authors:  Yury I Miller; Sotirios Tsimikas
Journal:  Curr Opin Lipidol       Date:  2013-10       Impact factor: 4.776

3.  Alpha linolenic acid decreases apoptosis and oxidized phospholipids in cardiomyocytes during ischemia/reperfusion.

Authors:  Riya Ganguly; Devin Hasanally; Aleksandra Stamenkovic; Thane G Maddaford; Rakesh Chaudhary; Grant N Pierce; Amir Ravandi
Journal:  Mol Cell Biochem       Date:  2017-06-20       Impact factor: 3.396

4.  Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.

Authors:  Young Sup Byun; Jun-Hee Lee; Benoit J Arsenault; Xiaohong Yang; Weihang Bao; David DeMicco; Rachel Laskey; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2015-04-07       Impact factor: 24.094

5.  Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy-Brief Report.

Authors:  Daniel S Hippe; Binh An P Phan; Jie Sun; Daniel A Isquith; Kevin D O'Brien; John R Crouse; Todd Anderson; John Huston; Santica M Marcovina; Thomas S Hatsukami; Chun Yuan; Xue-Qiao Zhao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-04       Impact factor: 8.311

6.  HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a).

Authors:  Calvin Yeang; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2015-05-26       Impact factor: 5.922

7.  Immunopathology of desialylation: human plasma lipoprotein(a) and circulating anti-carbohydrate antibodies form immune complexes that recognize host cells.

Authors:  P S Sabarinath; P S Appukuttan
Journal:  Mol Cell Biochem       Date:  2015-01-30       Impact factor: 3.396

8.  Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction.

Authors:  Andrew P DeFilippis; Ilya Chernyavskiy; Alok R Amraotkar; Patrick J Trainor; Shalin Kothari; Imtiaz Ismail; Charles W Hargis; Frederick K Korley; Gregor Leibundgut; Sotirios Tsimikas; Shesh N Rai; Aruni Bhatnagar
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

9.  Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine.

Authors:  Ayelet Gonen; Lotte F Hansen; William W Turner; Erica N Montano; Xuchu Que; Apaїs Rafia; Meng-Yun Chou; Philipp Wiesner; Dimitrios Tsiantoulas; Maripat Corr; Michael S VanNieuwenhze; Sotirios Tsimikas; Christoph J Binder; Joseph L Witztum; Karsten Hartvigsen
Journal:  J Lipid Res       Date:  2014-08-20       Impact factor: 5.922

Review 10.  Zebrafish models of dyslipidemia: relevance to atherosclerosis and angiogenesis.

Authors:  Longhou Fang; Chao Liu; Yury I Miller
Journal:  Transl Res       Date:  2013-10-02       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.